相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
Deepak Raj et al.
GUT (2019)
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Alexander J. Muller et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Sachet A. Shukla et al.
CELL (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andree Forget et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells
Jing Li et al.
IMMUNITY (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression (vol 128, pg 805, 2018)
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer
Alessandra Metelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
The global landscape of cancer cell therapy
Jun Tang et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Ludmila Danilova et al.
CANCER IMMUNOLOGY RESEARCH (2018)
New developments in the management of head and neck cancer - impact of pembrolizumab
Khalil Saleh et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
David H. Munn et al.
CANCER RESEARCH (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
Induction and transcriptional regulation of the co-inhibitory gene module in T cells
Norio Chihara et al.
NATURE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Xiaojuan Liu et al.
CELL REPORTS (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
DNA repair defects and implications for immunotherapy
Katherine M. Bever et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Trends in the global immuno-oncology landscape
Jun Tang et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Immune checkpoint inhibitors for urothelial carcinoma
Hyung Suk Kim et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression
Zhenhua Ren et al.
CLINICAL CANCER RESEARCH (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
The potential and promise of IL-15 in immuno-oncogenic therapies
Tanya O. Robinson et al.
IMMUNOLOGY LETTERS (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Is CD47 an innate immune checkpoint for tumor evasion?
Xiaojuan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Jun Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
CAR-Ts move beyond B-cell cancers to myeloma
Elie Dolgin
NATURE BIOTECHNOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Sharareh Gholamin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor
Tomasz Maj et al.
NATURE IMMUNOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Saleh Rachidi et al.
SCIENCE IMMUNOLOGY (2017)
Applications of Immunogenomics to Cancer
X. Shirley Liu et al.
CELL (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
How One Thing Led to Another
Irving Weissman
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Current progress in immunotherapy for pancreatic cancer
Kelly Foley et al.
CANCER LETTERS (2016)
Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer
Alessandra Metelli et al.
CANCER RESEARCH (2016)
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Weimin Wang et al.
CELL (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Nadeem Riaz et al.
NATURE GENETICS (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
GP96 is a GARP chaperone and controls regulatory T cell functions
Yongliang Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Immunogenicity of somatic mutations in human gastrointestinal cancers
Eric Tran et al.
SCIENCE (2015)
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Julia Cuende et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
High-resolution genomic analysis: the tumor-immune interface comes into focus
Jonathan J. Havel et al.
GENOME BIOLOGY (2015)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy
L. Zhang et al.
GENE THERAPY (2013)
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Xuanming Yang et al.
MOLECULAR THERAPY (2013)
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
Zhihong Chi et al.
BMC CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses
Weiyi Peng et al.
CLINICAL CANCER RESEARCH (2010)
GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells
Dat Q. Tran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Expression of GARP selectively identifies activated human FOXP3+regulatory T cells
Rui Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Identification of a Regulatory T Cell Specific Cell Surface Molecule that Mediates Suppressive Signals and Induces Foxp3 Expression
Rui Wang et al.
PLOS ONE (2008)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes
HD Dong et al.
IMMUNITY (2004)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
